• Optimizing pharmacokinetics to maximize tumor uptake and penetration while minimizing off-target exposure and systemic toxicities
• Enhancing therapeutic precision by delivering potent alpha or beta-emitting radioisotopes to selectively destroy cancer cells
• Expanding target scope to address both high- and low-expressing cancer cells, enabling broad applicability across diverse tumor types

New Company for 2026